NCT06948955 2026-04-02
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.
Available
Clinical Trials
22 trialsNCT05041036 2026-04-01
Individual Patient Compassionate Use of Nirogacestat
SpringWorks Therapeutics, Inc.
Available
NCT07502716 2026-03-31
Compassionate Use of Ubamatamab
Regeneron Pharmaceuticals
Available
NCT07215832 2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT06617572 2026-02-09
Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
USWM, LLC (dba US WorldMeds)
Available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT04681248 2025-08-03
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
Leap Therapeutics, Inc.
No longer available
NCT03842865 2025-06-05
Expanded Access of Vigil in Solid Tumors
Gradalis, Inc.
Temporarily not available
NCT06751524 2024-12-30
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Available
NCT03994627 2024-12-16
Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
Eli Lilly and Company
Approved for marketing
NCT04714086 2024-10-24
Expanded Access Program for Avapritinib
Blueprint Medicines Corporation
No longer available
NCT04225429 2024-10-01
Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma
Ipsen
No longer available
NCT03874455 2024-03-22
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Ipsen
No longer available
NCT02822495 2023-06-15
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Atara Biotherapeutics
No longer available
NCT05612191 2022-11-28
Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)
Advenchen Laboratories, LLC
Available
NCT03862885 2020-07-27
Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
Approved for marketing
NCT04148092 2020-05-29
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
Deciphera Pharmaceuticals, LLC
Approved for marketing
NCT00210665 2017-10-10
A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
Janssen Research & Development, LLC
No longer available
NCT01689376 2016-08-16
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
Bayer
No longer available
NCT02570412 2015-10-22
Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy
CytRx
No longer available
NCT01613053 2015-04-24
MACS2226
Novartis
No longer available
NCT01646593 2014-12-15
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
Bayer
No longer available